A Phase 1 interventional study of KITE-363 and Fludarabine in Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis and Multiple Sclerosis, sponsored by Kite, A Gilead Company. Recruiting at 10 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Kite, A Gilead Company (part of Gilead Sciences) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States — 20 open to participants now, 25 under way, 10 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States.
Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, this one is the 26th largest by planned enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 23 of the 24 other live ones, and was the 53rd registered.
137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.
Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →20 of the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States are open now. Recruiting first, the newest first:
Kedrion S.p.A. · Sites in United States
Ages 18+
Grifols Therapeutics LLC · Sites in United States, Czechia, Poland and 1 more country
Ages 18+
argenx · Sites in United States, Argentina, Austria and 22 more countries
Ages 18+
argenx · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
argenx · Sites in United States, Germany
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 16 · Phase 4 2
First in 1990; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 57 is above the median of 39 across 84 interventional studies indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.
Median enrollment 74 across the 42 interventional studies, 120 across the 12 observational. Of the 28 that completed or were terminated, 14 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kite, A Gilead Company, one of the names counted as Gilead Sciences. Under that name alone:
Kite, A Gilead Company is the lead sponsor of 40 studies on the registry; 8 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 16 (84%) have results posted.
Gilead Sciences has 1 study filed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating — fewer than ten, so there is no comparison to draw.
10 of the studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05327114Phase 3Janssen Research & Development, LLCEfficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 2026-12-15 |
| NCT06290141Phase 3SanofiA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 2027-07-09 |
| NCT06920004Phase 3argenxA Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP | 2027-09 |
| NCT07091630Phase 3argenxA Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP | 2027-10-07 |
| NCT06680037TG Therapeutics, Inc.A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 55 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.
The primary objectives of this study are:
The criteria were revised on the registry on Oct 19, 2026. See what changed
Key Inclusion Criteria:
Reproductive status-related eligibility and requirements:
Inclusion Criteria for multiple sclerosis (MS):
MS (Relapsing and progressive forms):
Relapsing forms of MS (relapsing-remitting multiple sclerosis (RRMS), active secondary-progressive multiple sclerosis (aSPMS)):
Progressive forms of MS (primary-progressive multiple sclerosis (PPMS) and non-active secondary-progressive multiple sclerosis (naSPMS)):
Inclusion Criteria for myasthenia gravis (MG):
Inclusion Criteria for chronic inflammatory demyelinating polyneuropathy (CIDP):
Probable or definite CIDP as defined by the 2010 European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria, relapsing or progressive forms. Individuals with confirmed IgG4 paranodal antibodies (eg, NF155, CNTN1, Caspr1) are eligible if they meet EFNS/PNS 2010 criteria
Key Exclusion Criteria:
Exclusion Criteria for MS:
Exclusion Criteria for MG:
Exclusion Criteria for CIDP:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with relapsing forms of multiple sclerosis (RMS), progressive forms of multiple sclerosis (PMS), myasthenia gravis (MG), and/or chronic inflammatory demyelinating polyneuropathy (CIDP) will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by infusion of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose.
Biological: KITE-363 · Drug: Fludarabine · Drug: Cyclophosphamide
Participants with RMS, PMS, MG, and/or CIDP will receive infusion of KITE-363 CAR transduced autologous T cells at a single dose level, with different participants receiving sequential dose-escalation levels to find the Phase 1b recommended dose.
Biological: KITE-363
Participants with RMS, PMS, MG, and/or CIDP will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed Phase 1a recommended dose of KITE-363 CAR T cells.
Biological: KITE-363 · Drug: Fludarabine · Drug: Cyclophosphamide
A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.
Administered intravenously
Administered intravenously
Phase 1a: Percentage of Participants Experiencing Treatment-emergent Adverse Event (TEAEs)
Time frame: Up to 3 years
Phase 1a: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363
Time frame: Up to 28 days
Phase 1b: (All Cohorts) Percentage of Participants Experiencing TEAEs
Time frame: Up to 3 years
Phase 1b: Relapsing Forms of MS (RRMS) and Active Secondary-progressive Multiple Sclerosis (aSPMS): Number of New T1 Gadolinium Enhancing (GadE+) Lesions on Magnetic Resonance Imaging (MRI) at Week 12
This will be reported in participants with relapsing forms of Multiple Sclerosis MS (RRMS) and (aSPMS).
Time frame: Week 12
Phase 1b: Relapsing Forms of MS (RRMS and aSPMS): Number of New and/or Enlarging T2 Lesions on MRI at Week 12
Time frame: Week 12
Phase 1b: Progressive Forms of MS (PPMS) and Non-active Secondary-progressive Multiple Sclerosis (naSPMS): Time to Onset of Confirmed Disability Progression Over 12 Weeks (CDP-12)
Time frame: Up to 3 years
Phase 1b: Myasthenia Gravis (MG): Proportion of Participants of MG Activities of Daily Living (MG-ADL) Responders
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.
Time frame: Up to 3 years
Phase 1b: CIDP: Proportion of Participants with a ≥ 2 Points Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
Clinical improvement will be analyzed using adjusted inflammatory neuropathy cause and treatment (aINCAT) scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with chronic inflammatory demyelinating polyneuropathy (CIDP). The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate clinical improvement.
Time frame: Up to 3 years
Relapsing forms of MS (RRMS and aSPMS): Annual Relapse Rate
Proportion of participants with annual relapse.
Time frame: Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-12
Time frame: Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Proportion of Participants With CDP-24
Time frame: Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-12
Time frame: Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Time to Onset of CDP-24
Time frame: Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Proportion of Participants with No Evidence of Disease Activity (NEDA)
Time frame: Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Expanded Disability Status Scale (EDSS) Score Over Time
EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments.
Time frame: Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Timed 25-foot Walk (T25FW) Score Over Time
The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment.
Time frame: Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in 9-hole Peg Test Dominant/Non-dominant (9-HPT D/ND) Score Over Time
The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability.
Time frame: Up to 3 years
Relapsing Forms of MS (RRMS and aSPMS): Change From Baseline in Symbol Digit Modalities Test (SDMT) Score Over Time
SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed.
Time frame: Up to 3 years
Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-12
Time frame: Up to 3 years
Progressive Forms of MS (PPMS and naSPMS): Proportion of Participants with CDP-24
Time frame: Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Time to Onset of CDP-24
Time frame: Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Number of new and Enlarging T2 Lesions on MRI
Time frame: Up to 3 years
Relapsing forms of MS (RRMS and aSPMS): Percentage of Participants With NEDA
Time frame: Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in EDSS Over Time
EDSS is scale used to measure disability and disease progression in participants with MS. It ranges from 0 (normal neurological exam) to 10 (death due to MS) in 0.5-point increments.
Time frame: Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in T25FW Over Time
The T25FW is a performance-based measure used in people with MS to assess walking speed and mobility. Lower times indicate better walking ability, while longer times reflect greater impairment.
Time frame: Up to 3 years
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in 9-HPT D/ND Over Time
The 9-HPT assesses hand dexterity and fine motor function by timing how long it takes a participant to place and remove nine pegs from a board. Faster times indicate better function, while slower times reflect greater disability.
Time frame: Up to 2 years
Progressive forms of MS (PPMS and naSPMS): Change From Baseline in SDMT Over Time
SDMT is a performance-based cognitive assessment to measure information processing speed. The score is the number of correct responses completed in the time limit, with higher scores indicating better cognitive processing speed.
Time frame: Up to 3 years
MG: Proportion of Participants With at Least a 2-Point or 5 Point Improvement in MG-ADL Score up to Week 24
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.
Time frame: Up to 24 weeks
MG: Change From Baseline in MG-ADL Score at Week 24
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.
Time frame: Baseline, Week 24
MG: Proportion of Participants With Minimal Symptom Expression (MG-ADL Score of 0 or 1 Point)
The MG-ADL is a scale to measure the functional impact of MG on daily activities. The total score ranges from 0 to 24, with higher scores indicating greater disability and disease burden.
Time frame: Up to 3 years
MG: Proportion of Participants With at Least a 3-point or 5-point Improvement in Medical Research Council (QMG) Score up to Week 24
The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment.
Time frame: Baseline, Week 24
MG: Change From Baseline in QMG Score to Week 24
The QMG test is a standardized quantitative strength scoring system developed specifically for MG. The total QMG score is the sum of the scores for 13 items, with a possible maximum score of 39. A higher score indicates more severe disease involvement, while a lower score suggests less functional impairment.
Time frame: Baseline, Week 24
MG: Proportion of Participants With at Least a 3-Point Improvement in MG-C Score up to Week 24
MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment.
Time frame: Baseline, Up to 24 weeks
Change From Baseline in MG-C Scale Score at Week 24
MG-C scale is a tool that measures disease severity in MG. The total score ranges from 0 to 50, with higher scores indicating greater impairment.
Time frame: Baseline, Week 24
MG: Number of Participants With Changes in Myasthenia Gravis Foundation of American Post-Intervention Status (MGFA-PIS), Including Minimal Manifestation, Complete Stable Remission, Pharmacologic Remission
The MGFA-PIS is a standardized classification system which categorizes outcomes into distinct states such as complete stable remission (CSR), pharmacologic remission (PR), minimal manifestations (MM), improved, unchanged, worse, and exacerbation. CSR indicates no symptoms or signs for at least one year without therapy, while MM reflects minimal weakness without functional limitation.
Time frame: Up to 3 years
CIDP: Proportion of Participants With a ≥ 1-point Improvement from Baseline in aINCAT Score at Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.
Time frame: Week 24
Proportion of Participants With a ≥ 2-point Improvement from Baseline in aINCAT Score at Week 24
Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.
Time frame: Week 24
Proportion of Participants Without aINCAT Deterioration and Without Requirement for CIDP Rescue or Maintenance Therapy Through Week 24
Time frame: Up to Week 24
Proportion of Participants With ≥ 1-point Improvement in INCAT Lower Limb Score from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
Clinical improvement will be analyzed using INCAT scale. The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.
Time frame: Baseline, up to Week 24
Proportion of Participants Transitioning from INCAT Lower Limb score ≥ 3 (Assistive Device) to ≤ 2 (Independent Ambulation) from Baseline to Week 24, in the Absence of CIDP Rescue Therapy or Initiation of New Maintenance Immunomodulatory Therapy
The INCAT score is a clinician administered tool used to assess functional disability in participants with CIDP. The total scores range from 0 to 10, higher scores indicating greater disability and lower score would indicate improvement.
Time frame: Baseline, up to Week 24
CIDP: Time to First aINCAT Deterioration
INCAT is a clinician-administered tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability and lower score would indicate clinical improvement.
Time frame: Up to 3 years
CIDP: Proportion of Participants With Evidence of Clinical Improvement
Clinical improvement will be analyzed using inflammatory Rasch-built overall disability scale (I-RODS) scale. I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability.
Time frame: Up to week 24
CIDP: Change From Baseline Over Time in Adjusted INCAT Score
INCAT is a tool used to assess functional disability in participants with CIDP. The total score ranges from 0 to 10, where higher scores indicate greater disability.
Time frame: Up to 3 years
CIDP: Change From Baseline Over Time in 24-Item I-RODS Score
I-RODS is a scale that assesses activity and participation limitations in people with CIDP. The score ranges from 0 to 48, with higher scores indicating better functional ability.
Time frame: Up to 3 years
CIDP: Change From Baseline Over Time in Medical Research Council (MRC) Sum Score
MRC Sum Score is a measure to assess muscle strength for people with CIDP. The score ranges from 0 to 60. Higher scores indicate better muscle strength, while lower scores reflect greater weakness.
Time frame: Up to 3 years
CIDP: Change From Baseline Over Time in Timed Up and Go (TUG) Score
TUG test is a measure of mobility, balance, and fall risk. The score is recorded in seconds; shorter times indicate better mobility, while longer times suggest impaired balance or gait.
Time frame: Up to 3 years
CIDP: Change From Baseline Over Time in Mean Grip Strength
Mean Grip Strength is a quantitative measure of hand and forearm muscle strength. Higher values indicate better muscle strength, while lower values reflect weakness or functional impairment.
Time frame: Up to 3 years
Proportion of Participants With European Quality of Life 5-Dimension 5-Level Questionnaire (EQ-5D-5L)
The EQ-5D-5L is a generic measure of health status captured on the day of assessment. Two components comprise the EQ-5D-5L: the EQ-5D descriptive system and the EQ visual analog scale (VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and is divided into 5 levels of severity: "no problems," "slight problems," "moderate problems," "severe problems," and "extreme problems." The EQ-5D-5L VAS is a vertical VAS for recording self-rated current HRQoL, and it ranges from 0, described as "the worst health you can imagine," to 100, described as "the best health you can imagine." EQ-5D-5L will be scored according to the published administration and scoring manual.
Time frame: Up to 3 years
Proportion of Participants With Chronic Acquired Polyneuropathy Patient-reported Index (CAP-PRI)
The CAP-PRI is a tool developed to assess the impact of chronic acquired polyneuropathy on participant's quality of life, capturing both physical and psychological symptoms from the participant's perspective. The scoring of the CAP-PRI is typically based on how participants rate their symptoms and overall health across various dimensions, such as sensory symptoms, motor function, pain, emotional well-being, and fatigue. Each dimension of the CAP-PRI is scored separately, and the results are summed up to give an overall score for the participant, with higher scores indicating greater severity or a worse quality of life. Each domain typically uses a Likert scale or similar ordinal scale, where participants rate their experience or symptoms on a scale from 0 to 5.
Time frame: Up to 3 years
Proportion of Participants With Rasch-Transformed Fatigue Severity Scale (RT-FSS)
The RT-FSS or FSS-7 is a refined version of the original 9-item Fatigue Severity Scale (FSS-9) designed to improve accuracy in measuring fatigue, particularly in participants with immune-mediated neuropathies. The original 7-point Likert scale was collapsed into a 4-point response category for the remaining items to fulfill strict linearity requirements. It is a linearly weighted scale, meaning its scores provide a more precise, interval-level measurement rather than just an ordinal ranking. It was specifically validated for conditions like Guillain-Barré syndrome and CIDP. This modified scale provides a more stable test-retest reliability. The scale is used to distinguish between different levels of fatigue impact on daily activities, though it may have a ceiling effect for patients with extremely severe symptoms.
Time frame: Up to 3 years
Levels of T-cells in Blood
Time frame: Up to 2 years
Pharmacokinetics: Levels of Chimeric Antigen Receptor (CAR) T-cells in Blood
Time frame: Up to 2 years
Pharmacodynamics Parameters: Levels of B cells in Blood
Time frame: Up to 2 years
Pharmacodynamics Parameters: Levels of Disease-Specific Biomarkers and Autoantibodies in Blood
Time frame: Up to 2 years
Pharmacodynamics Parameters: Levels of Cytokines and Chemokines in Blood
A panel of inflammatory, immuno-modulatory and effector molecules, including cytokines and chemokines, will be measured as units of concentration in serum (e.g. pg/ml) using ligand-based immunoassays such as MSD, Ella and O-link.
Time frame: Up to 2 years
Proportion of Participants With of Antibodies Against the KITE-363 CAR T cells in Blood
Time frame: Up to 2 years
Plan to share: No
Started Apr 2026 (actual). Primary completion is estimated for Dec 2031, 68 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jun 2029 → Dec 2031 and completion Jun 2029 → Dec 2031.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Autologous Anti-CD19/CD20 CAR-T Cells KITE-363
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating →